We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 10 november 2017

The Lancet: [Articles] Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lun...

[Articles] Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial
Addition of bevacizumab to adjuvant chemotherapy did not improve overall survival for patients with surgically resected early-stage NSCLC. Bevacizumab does not have a role in this setting and should not be considered as an adjuvant therapy for patients with resected early-stage NSCLC.
Read more

[News] Bosutinib more effective than imatinib in CML
Bosutinib might be a more effective first-line therapy than imatinib for patients with newly diagnosed chronic myeloid leukaemia (CML), according to results from the randomised, phase 3 BFORE trial.
Read more

[News] Biomarkers for subtypes of pancreatic ductal adenocarcinoma
Patients with pancreatic ductal adenocarcinoma have a poor prognosis, and those with advanced disease do not survive longer than 12 months, even after cancer treatment. One reason therapy might fail to improve survival is that pancreatic ductal adenocarcinoma could comprise several subtypes of disease, each requiring different treatments. Now, findings from a study by Alexander Muckenhuber (Technical University Munich, Munich, Germany) and colleagues suggest that subtypes identified by immunohistochemistry-based expression of cytokeratin 81 (KRT81) and hepatocyte nuclear factor 1A (HNF1A) have different survival outcomes and responses to chemotherapy.
Read more

[Comment] Bevacizumab in adjuvant treatment of non-small-cell lung cancer
Outcomes in early-stage non-small-cell lung cancer (NSCLC) are infamously poor. In the ANITA trial of patients with stage IB–IIIA disease,1 median overall survival for after surgical resection was 43·7 months. Use of adjuvant chemotherapy improved outcome but median overall survival was still only 65·7 months, and meta-analyses2 of NSCLC adjuvant chemotherapy trials suggest a relative survival benefit of just 5% at 5 years.2 When Heather Wakelee and colleagues designed the E1505 trial in 2007, the results of which are reported in The Lancet Oncology, there was a massive unmet need for better therapeutics.
Read more

[Articles] Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group
Both eBEACOPP variants met the co-primary efficacy endpoints. Particularly, the BrECADD regimen was associated with a more favourable toxicity profile and was, therefore, selected to challenge standard eBEACOPP for the treatment of advanced classical Hodgkin's lymphoma in the phase 3 HD21 study by the German Hodgkin Study Group (NCT02661503), which aims to further reduce treatment-related morbidity.
Read more